首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷內視鏡檢查設備

市場調查報告書

商品編碼

1733219

膠囊內視鏡市場（按配件、產品、應用和地區分類），2026 年至 2032 年

Capsule Endoscopy Market By Accessories (Wireless Capsule, Workstation and Receiver), By Product (Small Bowel, Esophageal), Application (Crohn's Disease, OGIB (Obscure Gastrointestinal Bleeding)), & Region for 2026-2032

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

膠囊內視鏡市場評估（2026-2032）

克隆氏症和消化道出血等疾病病例的增加推動了膠囊內視鏡檢查的普及。膠囊設計和成像技術的創新正在提高診斷準確性和患者體驗，推動市場規模在 2024 年超過 2.923 億美元，到 2032 年達到約 9.7156 億美元的估值。

這一點，加上人們對胃腸道健康和可用診斷選項的認知不斷提高，正在刺激膠囊內視鏡的採用。人們對非侵入性診斷方法的日益成長的偏好推動了患者對膠囊內視鏡的接受和使用，使市場在 2026 年至 2032 年期間的複合年成長率達到 16.20%。

膠囊內視鏡市場定義/概述

膠囊內視鏡檢查是一種微創診斷程序，透過吞下錠劑大小的小型相機來拍攝胃腸道（GI）的移動影像。該設備通常包含一個光源和一個鏡頭，可將影像無線傳輸到外部記錄設備。此技術可詳細觀察傳統內視鏡難以到達的消化道區域，例如小腸。

膠囊內視鏡主要用於診斷消化道出血、克隆氏症和小腸腫瘤。這對於出現不明原因胃腸道症狀的患者尤其有益，因為它可以全面檢查小腸，而小腸中的許多病變可能被忽略。該測試通常是安全的、非侵入性的並且不需要鎮靜，因此對許多患者來說是一個有吸引力的選擇。

胃腸道疾病的日益普及將如何促進膠囊內視鏡檢查的普及？

胃腸道疾病盛行率的上升是膠囊內視鏡市場發展的主要驅動力。根據美國國家糖尿病、消化和腎臟疾病研究所的數據，美國約有 6,000 萬至 7,000 萬人患有消化系統疾病。不斷成長的患者群體正在推動對微創診斷工具的需求。膠囊內視鏡檢查提供了一種無痛且有效的方法來觀察整個小腸，而使用傳統的內視鏡技術很難檢查。 2024 年 3 月，Medtronic宣布推出新款 PillCam(TM) SB4 系統，具有增強的影像處理功能和更長的電池壽命。

膠囊內視鏡系統的技術進步正在推動市場成長。更高解析度的攝影機、更長的電池壽命和人工智慧輔助影像分析等技術創新正在提高診斷準確性並擴大膠囊內視鏡的應用範圍。這些發展對於小腸腫瘤和不明原因的消化道出血的檢測尤其重要。世界衛生組織 (WHO) 報告稱，2020 年大腸癌將成為全球第三大常見癌症，新增病例數將達到 193 萬人。為了滿足這一日益成長的需求，Olympus Corporation於 2024 年 2 月宣布推出採用基於 AI 的病變檢測演算法的下一代膠囊內視鏡平台。

向基於價值的醫療保健的轉變和遠端醫療的日益普及正在推動膠囊內視鏡市場向前發展。膠囊內視鏡檢查是一種比傳統內視鏡檢查更具成本效益的替代方法，可減少住院和麻醉的需要。美國醫療保險和醫療補助服務中心報告稱，在新冠疫情期間，遠端醫療就診量增加了 63 倍，從 2019 年的約 84 萬次增加到 2020 年的 5,270 萬次。這一趨勢仍在持續，為遠端膠囊內視鏡檢查創造了機會。

膠囊內視鏡檢查的報銷選擇有限是否會限制市場成長？

由於該技術高成本，膠囊內視鏡市場面臨重大限制。除了所需的影像處理和讀取軟體外，設備本身也很昂貴。這種經濟負擔通常會限制病患和醫療機構的可近性，特別是在醫療預算緊張的開發中地區。高成本也阻礙了醫療保健提供者採用這項技術，從而限制了整體市場的成長。

另一個阻礙因素是膠囊內視鏡檢查的報銷選擇相對有限。許多保險公司不承擔全部費用，這可能會阻礙患者和醫生選擇這種診斷工具。由於缺乏標準化的報銷指南，情況變得更加複雜，醫療保健提供者很難證明膠囊內視鏡檢查的成本與傳統方法相比是合理的。

此外，數據管理和分析方面的技術挑戰也阻礙了市場的發展。膠囊內視鏡產生的大量數據需要複雜的軟體進行處理和解釋。然而，目前的影像分析能力和診斷準確性可能不一致，導致人們擔心漏診和需要後續程序。這種不確定性可能會使醫療保健專業人員不再依賴膠囊內視鏡作為主要診斷工具，從而影響市場採用。

Rising cases of conditions like Crohn's disease and gastrointestinal bleeding is propelling the adoption of capsule endoscopy. Innovations in capsule design and imaging technology enhance diagnostic accuracy and patient experience is driving the market size surpass USD 292.3 Million valued in 2024 to reach a valuation of around USD 971.56 Million by 2032.

In addition to this, increased awareness about gastrointestinal health and available diagnostic options is spurring up the adoption of capsule endoscopy. The rising preference for non-invasive diagnostic methods drives patient acceptance and usage of capsule endoscopy is enabling the market grow at a CAGR of 16.20% from 2026 to 2032.

Capsule Endoscopy Market: Definition/ Overview

Capsule endoscopy is a minimally invasive diagnostic procedure that involves swallowing a small, pill-sized camera that captures images of the gastrointestinal (GI) tract as it travels through. The device, typically equipped with a light source and camera, transmits images wirelessly to an external recorder. This technique allows for detailed visualization of areas of the GI tract that are difficult to reach with traditional endoscopic methods, such as the small intestine.

Capsule endoscopy is primarily used for diagnosing conditions such as gastrointestinal bleeding, Crohn's disease, and small bowel tumors. It is particularly beneficial for patients who experience unexplained GI symptoms, as it provides a comprehensive view of the small intestine, where many pathologies may go unnoticed. The procedure is generally safe, non-invasive, and does not require sedation, making it an attractive option for many patients.

How will Rising Prevalence of Gastrointestinal Disorders Increase the Adoption of Capsule Endoscopy?

The rising prevalence of gastrointestinal disorders is a key driver of the capsule endoscopy market. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60 to 70 million people in the United States are affected by digestive diseases. This increasing patient population has led to a growing demand for minimally invasive diagnostic tools. Capsule endoscopy offers a painless and efficient method for visualizing the entire small intestine, which is challenging to examine using traditional endoscopic techniques. In March 2024, Medtronic announced the launch of their new PillCam(TM) SB4 system, featuring enhanced imaging capabilities and improved battery life.

Technological advancements in capsule endoscopy systems are fueling market growth. Innovations such as higher resolution cameras, longer battery life, and artificial intelligence-assisted image analysis are improving diagnostic accuracy and expanding the applications of capsule endoscopy. These developments are particularly crucial for detecting small bowel tumors and obscure gastrointestinal bleeding. The World Health Organization reported that colorectal cancer was the third most common cancer worldwide in 2020, with 1.93 million new cases. In response to this growing need, Olympus Corporation unveiled its next-generation capsule endoscopy platform in February 2024, incorporating AI-powered lesion detection algorithms.

The shift towards value-based healthcare and the increasing adoption of telemedicine are driving the capsule endoscopy market forward. Capsule endoscopy offers a cost-effective alternative to traditional endoscopic procedures, reducing the need for hospital stays and anesthesia. The Centers for Medicare & Medicaid Services reported that telehealth visits increased by 63-fold during the COVID-19 pandemic, from approximately 840,000 in 2019 to 52.7 million in 2020. This trend has persisted, creating opportunities for remote capsule endoscopy procedures.

Will Limited Reimbursement Options Available for Capsule Endoscopy Restrain the Market Growth?

The capsule endoscopy market faces significant limitations due to the high costs associated with the technology. The devices themselves, along with the necessary imaging and interpretation software, can be expensive. This financial burden often restricts accessibility for patients and healthcare facilities, particularly in developing regions where healthcare budgets are tighter. The high cost can lead to hesitancy among providers to adopt the technology, limiting its overall market growth.

Another restraint is the relatively limited reimbursement options available for capsule endoscopy procedures. Many insurance providers do not fully cover the costs, which can discourage both patients and physicians from opting for this diagnostic tool. The lack of standardized guidelines for reimbursement further complicates the situation, making it challenging for healthcare providers to justify the expense of capsule endoscopy compared to traditional methods.

Additionally, the market is hindered by technological challenges related to data management and analysis. The vast amount of data generated by capsule endoscopes requires sophisticated software for processing and interpretation. However, the current capabilities for image analysis and diagnostic accuracy can be inconsistent, leading to concerns about missed diagnoses or the need for follow-up procedures. This uncertainty can deter healthcare professionals from relying on capsule endoscopy as a primary diagnostic tool, impacting market adoption.

Category-Wise Acumens

Will Rise in Adoption of Wireless Capsule Endoscopy Bolster Capsule Endoscopy Market Growth?

Wireless capsule endoscopy has emerged as the dominant technology in the capsule endoscopy market, revolutionizing gastrointestinal diagnostics. This non-invasive method allows for comprehensive visualization of the small intestine, which is challenging to examine using traditional endoscopic techniques. The U.S. Food and Drug Administration (FDA) reports that since the approval of the first wireless capsule endoscopy system in 2001, over 2 million procedures have been performed worldwide. The technology's ability to provide high-resolution images while minimizing patient discomfort has led to its widespread adoption.

The wireless capsule's dominance is further reinforced by its expanding applications beyond small bowel examination. Recent advancements have enabled its use in esophageal and colon screenings, broadening its clinical utility. According to the National Institute of Diabetes and Digestive and Kidney Diseases, colorectal cancer is the third most common cancer in both men and women in the United States, with an estimated 151,030 new cases in 2022. This prevalence underscores the importance of effective screening tools like wireless capsule endoscopy.

Which Factors Enhance the Use of Capsule Endoscopy to Diagnose Obscure Gastrointestinal Bleeding (OGIB)?

Obscure Gastrointestinal Bleeding (OGIB) has emerged as the dominant application in the capsule endoscopy market, driving significant growth and innovation. OGIB, defined as persistent or recurrent bleeding from the gastrointestinal tract with no identifiable source through conventional endoscopy, presents a unique diagnostic challenge that capsule endoscopy is uniquely positioned to address. According to the National Institute of Diabetes and Digestive and Kidney Diseases, OGIB accounts for approximately 5% of all gastrointestinal bleeding cases, with the small bowel being the most common source. Capsule endoscopy's ability to visualize the entire small intestine has made it an invaluable tool in diagnosing OGIB.

The prevalence of OGIB and its impact on patient quality of life have spurred technological advancements in capsule endoscopy systems. These improvements include higher resolution cameras, longer operating times, and artificial intelligence-assisted image analysis, all aimed at enhancing the detection of subtle bleeding sources. The American Journal of Gastroenterology reported that capsule endoscopy has a diagnostic yield of up to 67% in patients with OGIB, significantly higher than other diagnostic modalities. This high diagnostic yield has solidified capsule endoscopy's position as the gold standard for OGIB diagnosis.

Country/Region-wise Acumens

Will Presence Of Major Market Players in North America Fuel the Capsule Endoscopy Market Growth?

North America dominates the capsule endoscopy market, driven by a high prevalence of gastrointestinal disorders and advanced healthcare infrastructure. The region's leadership is underpinned by early adoption of innovative medical technologies and a robust reimbursement landscape. According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the third most common cancer in both men and women in the United States, with 151,030 new cases reported in 2022. This high incidence rate has fueled demand for advanced diagnostic tools like capsule endoscopy. In January 2024, Medtronic, a key player in the North American market, launched its next-generation PillCam(TM) SB4 system, featuring improved image resolution and a longer battery life, further solidifying the region's dominance in capsule endoscopy technology.

The presence of major market players and ongoing research and development activities contribute significantly to North America's leading position. The region boasts a high concentration of key manufacturers, fostering innovation and competitive pricing. The U.S. Food and Drug Administration (FDA) reported that since the first capsule endoscopy system approval in 2001, over 2 million procedures have been performed in the United States alone. This high adoption rate reflects the region's advanced healthcare system and willingness to embrace new technologies. In March 2024, Olympus Corporation announced the opening of a new research and development center in California, focusing on AI-powered image analysis for capsule endoscopy, highlighting the region's continued investment in advancing this technology.

Will Improving Access to Advanced Medical Technologies Enhance Adoption of Capsule Endoscopy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the capsule endoscopy market, driven by increasing healthcare expenditure, rising awareness of gastrointestinal diseases, and improving access to advanced medical technologies. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and growing middle class contributing to increased demand for minimally invasive diagnostic tools. According to the World Health Organization, the incidence of colorectal cancer in Asia is expected to increase by 60% by 2030, reaching 1.5 million new cases annually. This alarming projection has spurred investment in early detection technologies.

Technological advancements and localization efforts by key market players are fueling the rapid growth of capsule endoscopy in Asia Pacific. The region's tech-savvy population and strong manufacturing capabilities have created a fertile ground for innovation in medical devices. The Indian Council of Medical Research reported that in 2023, there was a 15% increase in the adoption of capsule endoscopy procedures across major Indian hospitals compared to the previous year. This trend reflects the growing acceptance of the technology among healthcare providers and patients alike.

Competitive Landscape

The capsule endoscopy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the capsule endoscopy market include:

Given Imaging (Medtronic)
Olympus Corporation
Pentax Medical
FujiFilm Corporation
Siemens Healthineers
Check-Cap Ltd.
IntroMedic Co., Ltd.
Capsovision, Inc.
Medtronic
BSC (Boston Scientific Corporation)
Hoya Corporation
Echosens
Endocapsule (Olympus)
Motus GI Holdings, Inc.
STERIS plc
C2N Diagnostics
Medtronic (Acquisition of Given Imaging)
VGI Health Technology
Lumendi
Kallistem

Latest Developments

In September 2023, Medtronic announced the launch of its latest capsule endoscopy system, featuring advanced imaging technology that improves diagnostic accuracy for gastrointestinal disorders.
In August 2023, a collaborative study published in the Journal of Gastroenterology highlighted the increasing efficacy of capsule endoscopy in detecting early-stage colorectal cancer, leading to growing demand in the market.

1 INTRODUCTION OF GLOBAL CAPSULE ENDOSCOPY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CAPSULE ENDOSCOPY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CAPSULE ENDOSCOPY MARKET, BY ACCESSORIES

5.1 Overview
5.2 Wireless Capsule
5.3 Workstation and Receiver

6 GLOBAL CAPSULE ENDOSCOPY MARKET, BY PRODUCT

6.1 Overview
6.2 Small Bowel
6.3 Esophageal
6.4 Colon

7 GLOBAL CAPSULE ENDOSCOPY MARKET, BY APPLICATION

7.1 Overview
7.2 Crohn's Disease
7.3 OGIB (Obscure Gastrointestinal Bleeding)
7.4 Small Intestine Tumor
7.5 Others

8 GLOBAL CAPSULE ENDOSCOPY MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL CAPSULE ENDOSCOPY MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 CapsoVision
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Given Imaging
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 IntroMedic Co., Ltd.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 RF System lab
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Chongqing Jinshan Science & Technology (Group) Co., Ltd
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Olympus Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Fujifilm Holding Corporation
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments